Cyclosporine Drug Interactions

Wadhwa, Nand K.; Schroeder, T. J.; Pesce, A J; Myre, Steven A.; Clardy, Christopher; First, M R

doi:10.1097/00007691-198712000-00007

Cited by 68 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many drugs can interact with cyclosporin A (CsA) and affect its absorption, distribution, metabolism and/or excretion, possibly resulting in renal and/or extrarenal toxicities (1026,(1028)(1029)(1030). CsA is largely metabolized by the hepatic monoxygenase system, in particular cytochrome P450 (1026,1029).…”

Section: Medicationsmentioning

confidence: 99%

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

2001

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Medicationsmentioning

confidence: 99%

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

2001

American Journal of Transplantation

View full text Add to dashboard Cite

“…These drug interactions lead to increase or decrease of drug effects or other serious reactions. For example, cyclosporin, which is widely used as an immunosuppressant drug, is known to interact with many other drugs such as ketoconazole and erythromycin [1,2]. Cyclosporin is metabolized by CYP3A4, which is a member of a cytochrome P450 family and catalyzes the oxidation of a number of substrates, whereas, ketoconazole and erythromycin inhibit CYP3A4 enzyme activity.…”

Section: Introductionmentioning

confidence: 99%

Network Analysis of Adverse Drug Interactions

Takarabe

Okuda

Itoh

et al. 2008

Genome Informatics 2008

View full text Add to dashboard Cite

Harmful cffects associated with use of drugs are caused as a result of their side effects and combined use of different drugs. These drug interactions result in increased or decreased drug effects, or produce other new unwanted effects and are serious problems for medical institutions and pharmaceutical companies. In this study, we created a drug-drug interaction network from drug package inserts and characterized drug interactions. The known information about the potential risk of drug interactions is described in drug package inserts. Japanese drug package inserts are stored in the JAPIC (Japan Pharmaceutical Information Center) database and GenomeNet provides the GenomeNet pharmaceutical products database, which integrate the JAPIC and KEGG databases. We cxtracted drug interaction data from GenomeNet, where interactions are classified according to risks, contraindications or cautions for coadministration, and some entries include information about cnzymes metabolizing the drugs. We defined drug target and drug-metabolizing enzymes as interaction factors using information on them in KEGG DRUG, and classified drugs into pharmacological/chemical subgroups. In the resulting drug-drug interaction network, the drugs that are associated with the same interaction factors are closely interconnected. Mechanisms of these interactions were then identified by each interaction factor. To characterize other interactions without interaction factors, we used the A TC classification system and found an association between interaction mechanisms and pharmacological/chemical subgroups.

show abstract

“…Interactions can be anticipated if drugs that enhance or inhibit CsA metabolism are coadministered. Thus the enzyme inducing agents phenytoin, phenobarbitone and rifampicin all decrease CsA blood levels while ketoconazole, erythromycin, diltiazem, nicardipine and verapamil have been reported to increase CsA blood levels as a result of inhibition of metabolism (Castelao et al, 1988;Wadhwa et al, 1987). Washed muicrosomes (105,000 g pellets) were prepared using the classical differential sedimentation method as previously described (Purba et al, 1987).…”

Section: Introductionmentioning

confidence: 99%

Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.

Tjia

Back

Breckenridge

1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

The effects of four Ca2+ channel antagonists on the metabolism of cyclosporine (CsA) by human liver microsomes (n = 4) in vitro have been examined. Nicardipine produced marked inhibition of both M17 and M21 (IC50 = 7.0 microM) formation. In contrast nifedipine produced less than 20% inhibition of M17 and M21 even at the highest concentration examined (50 microM). Diltiazem data were comparable to those for nifedipine. Verapamil (50 microM) produced 30 and 28% inhibition of M17 and M21 formation, respectively. These findings give a basis to the increase in CsA blood concentrations seen in transplant patients who are also given nicardipine.

show abstract

Cyclosporine Drug Interactions

Cited by 68 publications

References 0 publications

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines

Network Analysis of Adverse Drug Interactions

Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.

Contact Info

Product

Resources

About